Faecalibacterium prausnitzii strains for treating and preventing gastrointestinal pain

Abstract

The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.

1 . A method of treating and/or preventing visceral abdominal pain in an individual, comprising
 administering to the individual a therapeutically effective amount of at least one  Faecalibacterium prausnitzii  bacterial strain belonging to phylogroup I, II and/or III.   
     
     
         2 . The method according to  claim 1 , wherein the at least one  Faecalibacterium prausnitzii  bacterial strain belongs to phylogroup I and/or phylogroup III. 
     
     
         3 . The method according to  claim 1 , wherein the at least one  Faecalibacterium prausnitzii  bacterial strain belongs to phylogroup I and is selected from the group consisting of bacterial strains deposited to the CNCM under accession numbers I-4542, I-4544 and I-4540. 
     
     
         4 . The method according to  claim 1 , wherein the at least one  Faecalibacterium prausnitzii  bacterial strain belongs to phylogroup III and is selected from the group consisting of bacterial strains deposited to the CNCM under accession numbers I-4574, I-4543, I-4575, I-4573, I-4644 and I-4546. 
     
     
         5 . The method according to  claim 1 , wherein the at least one  Faecalibacterium prausnitzii  bacterial strain is selected from the group consisting of bacterial strains deposited to the CNCM under the accession numbers I-4542, I-4544, I-4540, I-4574, I-4543, I-4575, I-4573, I-4644 and I-4546. 
     
     
         6 . The method according to  claim 1 , wherein the visceral abdominal pain is a gastrointestinal pain. 
     
     
         7 . The method according to  claim 1 , wherein the visceral abdominal pain is caused by a gastrointestinal disorder. 
     
     
         8 . The method according to  claim 7 , wherein the gastrointestinal disorder is a gastrointestinal hypersensitivity. 
     
     
         9 . The method according to  claim 1 , wherein the bacterial strain is comprised in a composition comprising a physiologically acceptable medium. 
     
     
         10 . A composition comprising, in a physiologically acceptable medium, at least one bacterial strain of  Faecalibacterium prausnitzii  selected from the group consisting of bacterial strains deposited to the CNCM under the accession numbers I-4542, I-4544, I-4540, I-4574, I-4543, I-4575, I-4573, I-4644 and I-4546. 
     
     
         11 . The composition according to  claim 10 , wherein the at least one bacterial strain of  Faecalibacterium prausnitzii  is the bacterial strain deposited to the CNCM under the accession number I-4573. 
     
     
         12 . The composition according to  claim 10 , wherein the composition is for oral administration and is selected from the group consisting of a food product, a drink, a pharmaceutical, a nutraceutical, a food additive, a food supplement and a dairy product. 
     
     
         13 . An isolated bacterial strain selected from the group consisting of bacterial strains deposited to the CNCM under the accession numbers I-4542, I-4544, I-4540, I-4574, I-4543, I-4575, I-4573, I-4644 and I-4546. 
     
     
         14 . The isolated bacterial strain according to  claim 13 , being the bacterial strain deposited to the CNCM under the accession number I-4573. 
     
     
         15 . The method of  claim 5 , wherein the at least one  Faecalibacterium prausnitzii  bacterial strain is a bacterial strain deposited to the CNCM under accession number I-4573. 
     
     
         16 . The method of  claim 6 , wherein the gastrointestinal pain is a colonic pain. 
     
     
         17 . The method according to  claim 7 , wherein the gastrointestinal disorder is a non-inflammatory gastrointestinal disorder. 
     
     
         18 . The method according to  claim 8 , wherein the gastrointestinal hypersensitivity is a colonic hypersensitivity selected from Irritable Bowel Syndrome and alternating-type Irritable Bowel Syndrome. 
     
     
         19 . The method according to  claim 9 , wherein the physiologically acceptable medium is a food supplement. 
     
     
         20 . The composition of  claim 12 , wherein the composition is a food supplement.